Pressmeddelande

BioStock: Spago Nanomedical progresses towards clinical phase with Tumorad

Cision Publicerad: 05 Jul 2022 10:02

Just before mid-year, Lund-based Spago Nanomedical announced that the company raised 58.4 MSEK in the completed capital round. The proceeds give the company the resources to maintain the pace in its two projects – SpagoPix in cancer diagnostics and Tumorad, in which it is developing a new radionuclide cancer treatment. BioStock reached out to CEO Mats Hansen for comments on recent events and what awaits in the coming six months.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/07/spago-nanomedical-progresses-towards-clinical-phase-with-tumorad/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Spago Nanomedical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!